{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:08Z","timestamp":1707524408477},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,19]]},"DOI":"10.7759\/cureus.19739","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T11:09:05Z","timestamp":1637320145000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response"],"prefix":"10.7759","author":[{"given":"Matthew  C","family":"Wilkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elgamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor  I","family":"Rybkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts. esophageal cancer. (2021). https:\/\/seer.cancer.gov\/statfacts\/html\/esoph.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2027-3","article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy","volume":"71","author":"Sym SJ","year":"2013","unstructured":"Sym SJ, Hong J, Park J, et al.. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013, 71:481-8. 10.1007\/s00280-012-2027-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.020","article-title":"Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801\/BIRIP trial)","volume":"50","author":"Higuchi K","year":"2014","unstructured":"Higuchi K, Tanabe S, Shimada K, et al.. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801\/BIRIP trial). Eur J Cancer. 2014, 50:1437-45. 10.1016\/j.ejca.2014.01.020","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0436","article-title":"Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma","volume":"14","author":"Joshi SS","year":"2018","unstructured":"Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 2018, 14:417-30. 10.2217\/fon-2017-0436","journal-title":"Future Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings HE","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015, 33:773-81. 10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo M","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, et al.. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015, 151:1206-12. 10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro K","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, et al.. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016, 17:717-26. 10.1016\/S1470-2045(16)00175-3","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah MA","year":"2019","unstructured":"Shah MA, Kojima T, Hochhauser D, et al.. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019, 5:546-50. 10.1001\/jamaoncol.2018.5441","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs CS","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al.. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018, 4:e180013. 10.1001\/jamaoncol.2018.0013","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.2","article-title":"Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study","volume":"37","author":"Kojima T","year":"2019","unstructured":"Kojima T, Muro K, Francois E, et al.. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019, 37:2. 10.1200\/JCO.2019.37.4_suppl.2","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143047","article-title":"Cutaneous events associated with immunotherapy of melanoma: a review","volume":"10","author":"Burzi L","year":"2021","unstructured":"Burzi L, Alessandrini AM, Quaglino P, Piraccini BM, Dika E, Ribero S. Cutaneous events associated with immunotherapy of melanoma: a review. J Clin Med. 2021, 10:3047. 10.3390\/jcm10143047","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3579","article-title":"Time-dependent measurement of adverse events","volume":"151","author":"Hwang SJ","year":"2015","unstructured":"Hwang SJ, Byth K, Fernandez-Penas P. Time-dependent measurement of adverse events. JAMA Dermatol. 2015, 151:1392. 10.1001\/jamadermatol.2015.3579","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/76226-pembrolizumab-induced-vitiligo-in-esophageal-squamous-cell-carcinoma-patient-with-durable-complete-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:11Z","timestamp":1707507011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/76226-pembrolizumab-induced-vitiligo-in-esophageal-squamous-cell-carcinoma-patient-with-durable-complete-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.19739","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}